<DOC>
	<DOCNO>NCT02163161</DOCNO>
	<brief_summary>Phase 1 , open label , single dose , 3 way crossover study evaluate bioavailability solid dose formulation PF 04965842 relative suspension formulation fast condition effect food bioavailability solid dosage formulation PF 04965842 healthy subject .</brief_summary>
	<brief_title>AStudy Evaluate Bioavailability PF 04965842 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male subject female subject non childbearing potential age 18 55 year , inclusive . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Subjects receive within 7 day prior first dose study medication likely receive study moderate strong inhibitor CYP3A4 , eg , itraconazole , erythromycin , ketoconazole , protease inhibitor , verapamil , diltiazem . Subjects receive within 28 day likely receive study inducer CYP3A4 , eg rifampin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Open Label</keyword>
	<keyword>Single dose</keyword>
	<keyword>Crossover</keyword>
	<keyword>Bioavailability</keyword>
	<keyword>Fasting</keyword>
	<keyword>Fed</keyword>
	<keyword>PF-04965842</keyword>
	<keyword>Healthy</keyword>
</DOC>